Key Highlights:
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on developing targeted protein degraders for the treatment of cancer and inflammatory/autoimmune diseases. It operates in the biotechnology sector, with a particular emphasis on the Zacks Medical – Biomedical and Genetics industry group.
On April 8, 2026, Nurix reported financial results for the fiscal first quarter ended February 28, 2026. The company posted an EPS of -$0.79, missing estimates (surprise of roughly -4.22%). This compares to an EPS of -$0.67 in the year-ago quarter. Over the past year, Nurix has beaten EPS estimates in only a limited number of quarters.
Revenue totaled $6.3 million, significantly below consensus estimates (shortfall of approximately 57%). This represents a sharp decline from $18.5 million in the same quarter last year, primarily due to the completion of the initial research term for certain targets under the Sanofi collaboration. Nurix has a mixed track record of beating revenue estimates in recent quarters.
Financially, Nurix remains well-capitalized with $540.7 million in cash, cash equivalents, and marketable securities as of February 28, 2026 (down from $592.9 million at the end of the prior quarter). The company reported a net loss of $87.2 million. Operating expenses rose, driven by higher R&D investment (approximately $84.1 million) as the company accelerates clinical programs, along with increased G&A costs (approximately $14.6 million). Note that collaboration-heavy biotechs like Nurix can show negative gross margins in reporting due to the classification of certain costs against collaboration revenue.
